In this phase II trial, 42 patients with BCLC stage B or C HCC are enrolled to receive cobolimab (anti-tim-3 antibody) 300 mg and dostarlimab (anti-PD-1 antibody) 500 mg on day 1 of each 21-day cycle for a maximum of 2 years, or until there is treatment failure. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.